Investor Presentation First Nine Months of 2022
65
Investor presentation First nine months of 2022
In STEP 1, people treated with semaglutide had a superior
weight loss of up to 16.9%
The pivotal STEP 1 trial showed greater than 16% weight loss
% change in
body weight
0
•
Data from STEP 1
-2
-4
-6
≈ 46%
Average age 46
Average BMI - 37.9 kg/m²
Placebo: -2.4%
•
74.1% women
-8
-10
-12
-14
-16
-18
Semaglutide: -16.9%
-20
0 48 12 16 20
28
36
44
52
60
68
Time since initiation (weeks)
Change in body weight in % depicts observed means since time of randomisation; trial product estimand.
BMI: body mass index; SF-36: Short Form (36) Health Survey; IWQOL-lite-CT: Impact of Weight on Quality of Life-Lite questionnaire
Novo NordiskⓇ
Improvements in lipid profiles as well as
C-reactive protein
Semaglutide improved health-related
quality of life as measured by SF-36 and
IWQOL-lite-CTView entire presentation